AGB101
AssetAlso NSC-760119, UCB 22059, UCB L059, Levetiracetam
Low-dose extended-release levetiracetam targeting SV2A to modulate neural hyperactivity.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- SV2A
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Parkinson disease psychosis
Phase 2, Active not recruiting, NCT05824728, clinicaltrials.gov, 8 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.